Cargando…

Convalescent plasma for patients with COVID-19

Detalles Bibliográficos
Autores principales:	Zeng, Furong, Chen, Xiang, Deng, Guangtong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2020
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293648/ https://www.ncbi.nlm.nih.gov/pubmed/32398379 http://dx.doi.org/10.1073/pnas.2006961117

Ejemplares similares

Clinical determinants for fatality of 44,672 patients with COVID-19
por: Deng, Guangtong, et al.
Publicado: (2020)

Characteristics of pregnant patients with COVID-19 and liver injury
por: Deng, Guangtong, et al.
Publicado: (2020)

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Risk and outcomes of breakthrough COVID‐19 infections in vaccinated immunocompromised patients: A meta‐analysis
por: Deng, Guangtong, et al.
Publicado: (2023)

Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients
por: Zhao, Deze, et al.
Publicado: (2023)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Clinical Significance of Plasma D-Dimer in COVID-19 Mortality
por: Li, Yayun, et al.
Publicado: (2021)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!
por: Sanfilippo, F., et al.
Publicado: (2020)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Use of convalescent plasma in hospitalized patients with COVID-19: case series
por: Hegerova, Livia, et al.
Publicado: (2020)

Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2022)

Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19
por: Kesici, Selman, et al.
Publicado: (2020)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Clinical outcomes of using plasma in COVID-19 convalescent critically ill patients
por: Astola Hidalgo, I., et al.
Publicado: (2023)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

Risk–benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19
por: Dhanasekaran, Sivaraman, et al.
Publicado: (2020)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

The anti-ferroptotic role of FSP1: current molecular mechanism and therapeutic approach
por: Zeng, Furong, et al.
Publicado: (2022)

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin
por: Gazzaruso, Carmine, et al.
Publicado: (2021)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia
por: McKemey, Emily, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_46ap0vatiambqg76vdataoc0j8